嬌生
JNJ207.640USD
-0.140-0.07%
收盤 12/26, 16:00（美東）報價延遲15分鐘
499.62B總市值
19.90本益比TTM
關於 嬌生 公司
嬌生公司（Johnson & Johnson）通過旗下子公司，專注醫療健康領域產品的研發、生產與全球行銷。公司聚焦提升人類健康與福祉，並分為 「Innovative Medicine（創新醫藥）」與「J&J MedTech（醫療科技）」 兩大業務 。Innovative Medicine 深耕免疫學、傳染病、神經科學、腫瘤學、肺動脈高壓、心血管和代謝疾病等治療領域。醫療科技部門提供骨科、外科、介入治療、心血管介入與視覺保健等產品，並因收購 Shockwave Medical 將其商用血管內碎石術 (IVL) 平台納入，用於 CAD 與 PAD 的微創治療 ；同時研發數據驅動的外科機器人與數位手術解決方案。
嬌生簡介
公司代碼JNJ
公司名稱Johnson & Johnson
上市日期Oct 31, 2080
CEODuato (Joaquin Boix)
員工數量138100
證券類型Ordinary Share
年結日Oct 31
公司地址One Johnson & Johnson Plaza
城市NEW BRUNSWICK
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編08933
電話17325242455
網址https://www.jnj.com/
公司代碼JNJ
上市日期Oct 31, 2080
CEODuato (Joaquin Boix)
嬌生公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
12.85K
+17.90%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
10.66K
--
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ms. Marillyn A. Hewson
Ms. Marillyn A. Hewson
Lead Independent Director
Lead Independent Director
3.00K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Oncology-DARZALEX
3.54B
14.91%
Immunology-STELARA
1.65B
6.96%
Cardiovascular-ELECTROPHYSIOLOGY
1.47B
6.18%
Surgery-General
1.39B
5.86%
Immunology-TREMFYA
1.19B
5.00%
其他
14.51B
61.10%
地區USD
名稱
營收
佔比
United States
13.54B
57.04%
Europe
5.39B
22.69%
Asia-Pacific, Africa
3.61B
15.19%
Western Hemisphere, excluding U.S.
1.21B
5.08%
業務
地區
業務USD
名稱
營收
佔比
Oncology-DARZALEX
3.54B
14.91%
Immunology-STELARA
1.65B
6.96%
Cardiovascular-ELECTROPHYSIOLOGY
1.47B
6.18%
Surgery-General
1.39B
5.86%
Immunology-TREMFYA
1.19B
5.00%
其他
14.51B
61.10%
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.78%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
其他
75.51%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.78%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
其他
75.51%
股東類型
持股股東
佔比
Investment Advisor
39.47%
Investment Advisor/Hedge Fund
24.27%
Research Firm
3.15%
Pension Fund
2.24%
Bank and Trust
2.16%
Insurance Company
1.61%
Sovereign Wealth Fund
1.41%
Hedge Fund
0.72%
Family Office
0.09%
其他
24.88%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
5885
1.79B
74.44%
+16.50K
2025Q2
5920
1.78B
73.89%
-7.65M
2025Q1
6002
1.80B
74.62%
+4.60M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
236.03M
9.8%
+3.04M
+1.31%
Jun 30, 2025
State Street Investment Management (US)
132.80M
5.51%
-992.45K
-0.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
129.76M
5.39%
+619.12K
+0.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
60.61M
2.52%
+1.23M
+2.06%
Jun 30, 2025
JP Morgan Asset Management
36.71M
1.52%
+1.46M
+4.13%
Jun 30, 2025
State Farm Insurance Companies
34.37M
1.43%
--
--
Jun 30, 2025
Norges Bank Investment Management (NBIM)
31.93M
1.33%
+1.57M
+5.18%
Jun 30, 2025
Wellington Management Company, LLP
24.88M
1.03%
+2.23M
+9.85%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
25.30M
1.05%
+1.23M
+5.13%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
19.85M
0.82%
+148.42K
+0.75%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares U.S. Pharmaceuticals ETF
23.7%
VanEck Pharmaceutical ETF
10.06%
FT Vest DJIA Dogs 10 Target Income ETF
9.82%
Health Care Select Sector SPDR Fund
9.32%
Proshares Ultra Health Care
9%
iShares U.S. Healthcare ETF
8.9%
JPMorgan Healthcare Leaders ETF
8.38%
First Trust NASDAQ Pharmaceuticals ETF
8.28%
Fidelity MSCI Health Care Index ETF
7.67%
Franklin Income Focus ETF
7.08%
查看更多
iShares U.S. Pharmaceuticals ETF
佔比23.7%
VanEck Pharmaceutical ETF
佔比10.06%
FT Vest DJIA Dogs 10 Target Income ETF
佔比9.82%
Health Care Select Sector SPDR Fund
佔比9.32%
Proshares Ultra Health Care
佔比9%
iShares U.S. Healthcare ETF
佔比8.9%
JPMorgan Healthcare Leaders ETF
佔比8.38%
First Trust NASDAQ Pharmaceuticals ETF
佔比8.28%
Fidelity MSCI Health Care Index ETF
佔比7.67%
Franklin Income Focus ETF
佔比7.08%
分紅派息
近5年累計派現
56.79B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
嬌生的前五大股東是誰？
嬌生的前五大股東如下：
The Vanguard Group, Inc.持有股份：236.03M佔總股份比例：9.80%。
State Street Investment Management (US)持有股份：132.80M佔總股份比例：5.51%。
BlackRock Institutional Trust Company, N.A.持有股份：129.76M佔總股份比例：5.39%。
Geode Capital Management, L.L.C.持有股份：60.61M佔總股份比例：2.52%。
JP Morgan Asset Management持有股份：36.71M佔總股份比例：1.52%。
The Vanguard Group, Inc.持有股份：236.03M佔總股份比例：9.80%。
State Street Investment Management (US)持有股份：132.80M佔總股份比例：5.51%。
BlackRock Institutional Trust Company, N.A.持有股份：129.76M佔總股份比例：5.39%。
Geode Capital Management, L.L.C.持有股份：60.61M佔總股份比例：2.52%。
JP Morgan Asset Management持有股份：36.71M佔總股份比例：1.52%。
嬌生的前三大股東類型是什麼？
嬌生 的前三大股東類型分別是：
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
有多少機構持有嬌生(JNJ)的股份？
截至2025Q3，共有5885家機構持有嬌生的股份，合計持有的股份價值約為1.79B，占公司總股份的74.44% 。與2025Q2相比，機構持股有所增加，增幅為0.55%。
哪個業務部門對嬌生的收入貢獻最大？
在FY2025Q2，Oncology-DARZALEX業務部門對嬌生的收入貢獻最大，創收3.54B，占總收入的14.91% 。
